ArticlePDF Available

Comparison of Ziziphus jujube Mill. Syrup versus polyethylene glycol in children with functional constipation: a randomized clinical trial

Springer Nature
Scientific Reports
Authors:

Abstract and Figures

Functional constipation is a common disorder of the gastrointestinal tract in children without specific treatment. Ziziphus jujuba has been used in traditional medicine for various diseases such as constipation. A safe and inexpensive treatment with few side effects can be used as an effective alternative to current medications. In this study, we sought to compare Ziziphus jujuba syrup (ZS) with polyethylene glycol (PEG) for the treatment of pediatric functional constipation. A double-blind, randomized clinical trial was performed on children aged 2–10 years with functional constipation who were referred to the gastroenterology clinic of the 17-Shahrivar Hospital in Rasht, Iran. Eligible patients were randomized into two groups: PEG group; 1–5 cc/kg/day (40% w/v solution without electrolytes; average dose: 0.2–1 g/kg), and ZS group; 1–5 cc/kg/day (average dose: 5–25 mg/kg). All patients were followed up for three months, every 2 weeks in the first month, and then monthly for 2 months. At the beginning and end of the study, liver and kidney function tests and blood sugar levels were checked. Data were analyzed using SPSS software version 19 at a significance level of 0.05. Out of 90 eligible children, 32 patients in the PEG group and 30 patients in the ZS group completed the follow-up visits. The mean age of the subjects was 4.31 ± 1.97 years. There was no significant difference between the two groups in terms of age (P = 0.181), gender (P = 0.218), age at onset of constipation (P = 0.083), and weight (P = 0.199). The average therapeutic response score in the ZS group improved prominently compared to the PEG group (P < 0.05). The average number of encopresis and visual analog scale pain scores significantly decreased in the ZS group compared to the PEG group (P < 0.05). Other indices, including frequency of defecation, and medication adherence in the ZS group were significantly improved compared to the PEG group (P < 0.05). Only in the PEG group, a few cases reported self-limiting side effects. ZS can be a treatment choice for functional constipation without any adverse events or liver or kidney injury in children. However, further studies are necessary to find potential side effects. Supplementary Information The online version contains supplementary material available at 10.1038/s41598-025-85801-w.
This content is subject to copyright. Terms and conditions apply.
Comparison of Ziziphus jujube
Mill. Syrup versus polyethylene
glycol in children with functional
constipation: a randomized clinical
trial
Fatemeh Keihanian1, Shohreh Maleknejad2, Amin Saeidinia3,4, Soheil Soltanipour5 &
Amir Pirooz2
Functional constipation is a common disorder of the gastrointestinal tract in children without
specic treatment. Ziziphus jujuba has been used in traditional medicine for various diseases such
as constipation. A safe and inexpensive treatment with few side eects can be used as an eective
alternative to current medications. In this study, we sought to compare Ziziphus jujuba syrup (ZS)
with polyethylene glycol (PEG) for the treatment of pediatric functional constipation. A double-blind,
randomized clinical trial was performed on children aged 2–10 years with functional constipation
who were referred to the gastroenterology clinic of the 17-Shahrivar Hospital in Rasht, Iran. Eligible
patients were randomized into two groups: PEG group; 1–5 cc/kg/day (40% w/v solution without
electrolytes; average dose: 0.2–1 g/kg), and ZS group; 1–5 cc/kg/day (average dose: 5–25 mg/kg). All
patients were followed up for three months, every 2 weeks in the rst month, and then monthly for 2
months. At the beginning and end of the study, liver and kidney function tests and blood sugar levels
were checked. Data were analyzed using SPSS software version 19 at a signicance level of 0.05. Out
of 90 eligible children, 32 patients in the PEG group and 30 patients in the ZS group completed the
follow-up visits. The mean age of the subjects was 4.31 ± 1.97 years. There was no signicant dierence
between the two groups in terms of age (P = 0.181), gender (P = 0.218), age at onset of constipation
(P = 0.083), and weight (P = 0.199). The average therapeutic response score in the ZS group improved
prominently compared to the PEG group (P < 0.05). The average number of encopresis and visual
analog scale pain scores signicantly decreased in the ZS group compared to the PEG group (P < 0.05).
Other indices, including frequency of defecation, and medication adherence in the ZS group were
signicantly improved compared to the PEG group (P < 0.05). Only in the PEG group, a few cases
reported self-limiting side eects. ZS can be a treatment choice for functional constipation without
any adverse events or liver or kidney injury in children. However, further studies are necessary to nd
potential side eects.
Keywords Functional constipation, Ziziphus jujube Mill., Polyethylene glycol, Clinical trial
Functional constipation is one of the most frequent complaints in childhood, which is oen dicult to manage1.
It accounts for more than 3% of visits to general pediatricians and 10–25% of pediatric gastroenterology
consultations2,3. Constipation is dened as infrequent and painful defecation, hard or large stools, and fecal
incontinence, usually associated with abdominal pain4,5. In about 95% of children suering from constipation,
no underlying pathological condition is responsible for the development of symptoms6. e global prevalence of
pediatric functional constipation varies from 0.7 to 29.6% (median 12%)79. e peak incidence of constipation
1Guilan Road Trauma Research Center, Trauma Institute, Guilan University of Medical Sciences, Rasht, Iran.
2Pediatric Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran. 3Pharmaceutical
Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
4Department of Pediatric, Ghaem Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad,
Iran. 5Department of Community Medicine, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.
email: shohremaleknejad@gmail.com
OPEN
Scientic Reports | (2025) 15:1674 1
| https://doi.org/10.1038/s41598-025-85801-w
www.nature.com/scientificreports
Content courtesy of Springer Nature, terms of use apply. Rights reserved
occurs during toilet training, between the ages of 2 and 4 years10. Genetic susceptibility, insucient uid and
ber intake, immobility, postponing defecation in public places, especially in schools, early or poor toilet training,
and introduction of solids during the process of weaning are some of the predisposing factors for functional
constipation11. e pathophysiology of this disorder is biopsychosocial, lacking an identiable structural or
biochemical etiology12. Withholding behavior is the most common etiology of functional constipation, usually
occurring aer an episode of painful defecation, which leads to a vicious cycle of stool withholding, pain, and
infrequent bowel movements13.
Functional constipation is diagnosed clinically, based on history, physical examination, and the ROME IV
criteria14,15. e delay in diagnosis and intervention leads to more severe functional constipation and a worse
prognosis16,17. Childhood constipation negatively impacts childrens physical, social, emotional, and school
functioning18. Treatment of functional constipation includes a combination of non-pharmacological and
pharmacological options19. Pharmacological treatment of functional constipation with laxatives comprises three
stages: disimpaction, maintenance therapy and nally weaning4.
Laxative drugs mainly include bulking, osmotic, lubricating, and stimulant agents20. Polyethylene glycol
(PEG) 3350 is widely prescribed as the rst-choice drug in pediatrics. Common side eects of PEG include
diarrhea, bloating, atulence, nausea, and abdominal pain3,21.
Lactulose, mineral oil, and magnesium hydroxide are prescribed as the second therapeutic options. However,
they are limited to certain age groups and can cause serious adverse eects22. ey have minimal therapeutic
eects but considerable side eects, while the symptoms tend to recur23. e evidence of non-pharmacological
modalities is weak24. erefore, nding an eective and safe therapeutic option for the treatment of functional
constipation in children is essential.
e trend of using natural-based drugs and complementary and alternative medicine is increasing25.
Ziziphus jujuba is one of the medicinal plants used as an analgesic, anticonvulsant, and anti-constipation in
the folk medicine of dierent countries2629. Clinical trials on Ziziphus fruit showed anti-inammatory,
antihyperglycemic, and anti-hyperlipidemic eects on type 2 diabetes mellitus patients30.
Medicinally active peptides such as cyclopeptide alkaloids, avonoids, sterols, jujuboside A, jujuboside B,
lauric acid, and triterpenoid saponins have been sequestered and chemically identied from various Ziziphus
species26. It has been considered safe in a wide range of doses31. Despite its laxative eects in traditional
medicines, there are limited investigations in the context of pediatric constipation. A previous study in the adult
population showed appropriate laxative eects32.
Material and methods
Study design and population
A prospective, double-blind, randomized controlled-trial (12-week follow-up) was conducted in the 17-Shahrivar
tertiary referral hospital in Rasht, Iran, from April 2020 to January 2021. Children aged between 2 and 10 years
who referred to the pediatric gastroenterology clinic with functional constipation were included in our study.
e sample size was calculated using the mean scores and standard deviation of the severity of pain based
on the visual analog scale (20 ± 19.9) in the study of Mozaarpur et al.33 by OpenEpi version 3 soware. Aer
calculating the dropout rate up to 10%, with power (1−β) = 0.90, and type I error probability and α = 0.01, a
sample size of 30 was obtained for each group.
Eligibility
Diagnosis of functional constipation was based on the ROME IV criteria aer ruling out organic causes by
history taking, physical examination, and laboratory tests. e physical examination consisted of a thorough
abdominal examination, evaluation of growth parameters, inspection of the perianal region (for ssures, skin
tags, polyps, or any obvious anomalies), and lumbosacral region (for pits, dimples, and creases), and a digital
rectal examination. Each patient was assessed in terms of red ags, abdominal distension, and fecal impaction in
the lower abdominal quadrant and hypogastric region.
Patients with organic causes of constipation (including hypothyroidism, Hirschsprung’s disease, celiac,
diabetes insipidus, cystic brosis, renal, cardiac, and neurological disorders), FTT or weight loss greater than
5%, those with a history of colorectal surgery and medication use in the last 3 months (such as antidepressants,
anticonvulsants, and sedatives), and children with fecal impaction were not eligible for study participation.
Patients with incomplete follow-up visits and those who declined to participate were excluded.
Randomization and blinding
Eligible patients were randomly allocated to PEG or ZS groups, by block randomization with a block size of
four (ratio 1:1). e order of the blocks was randomly determined in the PEG or ZS group, and the subjects
were assigned with the order of admission. A random allocation method was employed to determine sequences
using non-transparent envelopes sealed with random sequences (sequentially numbered, sealed, and opaque
envelopes).
e pediatric gastroenterologist (principal investigator) and patients/parents were both blinded to the
treatment allocation. Another medical practitioner not involved in the data analysis was unblinded to the
treatment groups and was responsible for allocating the drug to each patient and determining the dose. e
statistician was also blinded and used coded trial data in SPSS.
Intervention
In the PEG group, patients received oral PEG solution (Sepidaj Company, Iran) at a dose of 1–5cc/kg/day (0.2–1
g/kg) given as two divided doses. In the ZS group, oral consumption of Ziziphus jujuba syrup at a dose of 1–5cc/
kg/day (5–25mg/kg) was administered similarly in two divided doses. In both groups, treatment was continued
Scientic Reports | (2025) 15:1674 2
| https://doi.org/10.1038/s41598-025-85801-w
www.nature.com/scientificreports/
Content courtesy of Springer Nature, terms of use apply. Rights reserved
for a total of 12 weeks. All parents were educated about proper diet, including increased uid intake and dietary
ber, and behavioral modications such as a regular toileting schedule, sitting on the toilet for 5–10min aer
each meal, and considering rewards for appropriate toileting behavior.
PEG and ZS preparation and standards
e plant was identied and authenticated as a Ziziphus jujube Mill. by an academic pharmacognosist. e fruits
of Ziziphus jujuba Mill. were collected from Birjand, Iran, in September 2019. Five kilograms of fruits were
shade dried and coarsely powdered. About 3.3kg of powder was extracted with water and ethanol by percolation
method in the Faculty of Pharmacy, Mashhad, Iran by a pharmacist. Aer the extraction was completed, the
solvent was recovered by distillation and concentrated in vacuo. e formulation of syrup was prepared with
sucrose, distilled water, and sodium benzoate, and the syrup with 10% (v/v) of the extract was provided (the
concentration was 5mg/ml). All microbiologic, stability, and physicochemical tests of syrup were performed,
and total phenolic content and fructose content were determined by the HPLC method in the nal sample
(Supplementary Table S13).
PEG was initially prepared as a solution, in which 1cc contains 0.2 g of PEG. e PEG solution and ZS were
packaged in the same dark 250 mL glass bottles. To ensure successful blinding, only the treatment code and lot
number were placed on the outside of each bottle.
Assessment and follow-ups
For each patient, a checklist containing demographic data (age, sex, developmental status, age at onset of
constipation, surgical history) was completed. Frequency of defecation, stool consistency measured through the
Bristol Stool Form Scale, visual analog scale (VAS) pain score, presence of fecal incontinence, and other related
gastrointestinal symptoms (such as nausea, vomiting, atulence, and abdominal pain), and positive ndings in
the physical examination were documented at the rst visit. In addition, we used the scoring system of functional
constipation criteria according to the Karami et al. study34. To determine therapeutic response as a variable, we
calculated scores for the following variables at each visit: painful defecation, blood in stool, stool frequency per
week, number of encopresis per month, and stool consistency. e minimum score was six, and the maximum
was 21. erapeutic response was classied as follows: poor (6–10), moderate (11–15), and good (16–21).
All patients were visited every 2 weeks in the rst month, then monthly for 2 months (a total of 3 months).
Parents were requested to fulll a weekly checklist to record the number of defecations, encopresis, bloody stool,
VAS pain score, and fecal consistency according to the Bristol stool chart. In each visit, symptoms, adherence to
medication, and side eects were controlled. Medication adherence was evaluated based on the 4-item Morisky
scale35. Blood sugar levels and kidney and liver function tests were checked at the beginning and the end of the
trial for each participant. e primary endpoint was the VAS pain score, and the secondary one was adverse drug
events. Parents had access to an on-call physician in case of any complications or side eects.
Ethics declaration
is research was conducted in conformance with the principles stated in the Helsinki Declaration and was
approved by the ethical committee of Guilan University of Medical Sciences (Ethics code: IR.GUMS.REC.1397.157).
e study was also registered in the Iranian Registry of Clinical Trials (IRCT ID: IRCT20131006014915N3)
on 26/09/2018. Written informed consent was obtained from parents or legal guardians of all patients aer
explaining the purpose of the study.
Data analysis
All data were entered into SPSS soware version 19 (SPSS Inc. Chicago, Il, e USA). Descriptive statistics were
expressed as mean, standard deviation, frequency, and percent. e normal distribution of quantitative data
was evaluated by the Shapiro–Wilk test. e independent t-test was applied for normally distributed variables
and the Mann–Whitney test for non-normally distributed variables. For analysis of repetitive quantitative data
during the study follow-ups, the repeated measures ANOVA test was employed. e signicance level was set at
P < 0.05 in all tests.
Results
Forty-eight patients were assigned to the PEG group and 42 to the ZS group. However, during the study, 16
subjects in the PEG group and 12 subjects in the ZS group were excluded. e study owchart is depicted in
Fig.1.
e mean age of the subjects was 4.31 ± 1.97 years and 53.2% of them were females. ere was no statistically
signicant dierence between the two groups regarding the baseline demographic data (P > 0.05). Demographic
characteristics are presented in Table1.
As shown in Table2, baseline clinical manifestations of patients in both groups were not signicantly dierent
(P-value > 0.05).
Laboratory ndings
ere were signicant dierences in hemoglobin (P = 0.026) and TSH (P = 0.023) between ZS and PEG groups.
Other baseline laboratory data are listed in Table3.
Laboratory data at the last follow-up showed signicant dierences in AST (ZS group: 23.60 ± 6.81 vs. PEG
group: 33.35 ± 10.17; P = 0.003) and blood sugar levels (ZS group: 95.90 ± 9.56 vs. PEG group: 84.36 ± 9.40;
P = 0.005) between the two groups. Despite the statistically signicant dierence, it was not clinically relevant
and both of them were in the normal range.
Scientic Reports | (2025) 15:1674 3
| https://doi.org/10.1038/s41598-025-85801-w
www.nature.com/scientificreports/
Content courtesy of Springer Nature, terms of use apply. Rights reserved
Characteristics ZS group (n = 30) PEG group (n = 32) P-value
Abdominal distention, n (%) 2 (6.7) 1 (3.1) 0.475
Stool retention on the DRE, n (%) 6 (20) 13 (40.6) 0.068
Abnormal sphincter tone, n (%) 0 1 (3.1)
Anal ssure, n (%) 7 (23.3) 4 (12.5) 0.217
Tab le 2. Baseline clinical manifestations of patients in the ZS and PEG groups. ZS Ziziphus jujuba syrup, PEG
polyethylene glycol, DRE digital rectal examination.
Characteristics ZS group (n = 30) PEG group (n = 32) P-value
Gender, n (%) Male 12 (40) Male 17 (53.1) 0.218
Female 18 (54.5) Female 15 (46.9)
Age (mean ± S.D) years 4.66 ± 2.36 3.97 ± 1.48 0.181
Age at onset of constipation (mean ± S.D) months 37.40 ± 26.97 27.50 ± 16.19 0.083
Weight (mean ± S.D) kg 19.42 ± 7.83 17.17 ± 5.71 0.199
Familial history, n (%) 5 (16.7) 1 (3.1) 0.084
Tab le 1. Comparison of demographic data in the ZS and PEG groups. ZS Ziziphus jujuba syrup, PEG
polyethylene glycol, S.D standard deviation.
Fig. 1. e study owchart.
Scientic Reports | (2025) 15:1674 4
| https://doi.org/10.1038/s41598-025-85801-w
www.nature.com/scientificreports/
Content courtesy of Springer Nature, terms of use apply. Rights reserved
Clinical ndings
As shown in Table4, the therapeutic response in the ZS group was prominently better than the PEG group
at all follow-up visits (P = 0.001). In addition, the frequency of defecation in the ZS group was signicantly
higher than the PEG group at all follow-up intervals (P < 0.05; Fig.2a). e number of encopresis in the ZS
group signicantly decreased compared to the PEG group (P < 0.05; Fig.2b). VAS scores in the ZS group were
signicantly lower than the PEG group at weeks 4, 8, and 12 aer the intervention (P < 0.05; Fig.2c). In terms of
fecal consistency, there was no signicant dierence in the ZS group and PEG group at follow-up intervals (P>
0.05; Fig.2d).
Adverse events
Vomiting and abdominal pain were reported in the rst, second, and third weeks of the intervention in two
cases and in the fourth week in three cases of the PEG group. ere were no drug-related complications in the
ZS group. Improper consumption of the medication was reported in three cases of the PEG group in the second
week, in two cases of the PEG group in the third week, in ve cases of the PEG group and two cases of the ZS
group in the 12th week.
Medication adherence
Medication adherence of the patients at 2, 4, 8, and 12 weeks of follow-up was signicantly better in the ZS group
compared to the PEG group (P < 0.001) (Fig.3).
Discussion
Although pediatric constipation is a common chronic problem, few studies have compared dierent laxatives.
Among children who were referred to pediatric gastroenterologists, 50% would improve and be taken o
laxatives aer 6–12 months. About 10% of patients do well when using laxatives, and 40% will continue to have
symptoms despite using laxatives19. In this trial, we sought to compare the ecacy and safety of ZS and PEG
in children with functional constipation. To the best of our knowledge, this was the rst study to assess the
ecacy of ZS in pediatric functional constipation. Our ndings revealed that the mean therapeutic response
score, frequency of defecation, encopresis, and medication adherence were signicantly better in the ZS group
compared to the PEG group. e average number of encopresis and VAS pain score was signicantly decreased
in the ZS group than in the PEG group.
PEG is one of the choice therapeutic options, but children are not interested in its avor. Despite dierent
options in the treatment of functional constipation, there is limited evidence of their ecacy. Ziziphus jujube
fruit contains betulinic acid, oleanolic acid, maslinic acid, glucose, sitosterol, stigmasterol, desmosterol, resin,
Wee k 2 We ek 4 Wee k 8 Week 12
erapeutic response
PEG group 10.59 ± 1.77 11.09 ± 2.23 11.62 ± 2.73 11.62 ± 2.73
ZS group 13.03 ± 3.54 14.83 ± 3.64 15.10 ± 3.59 16.86 ± 4.56
P-value 0.001 0.001 0.001 0.001
Tab le 4. Comparison of therapeutic response in the ZS and PEG groups in follow-up visits. ZS Ziziphus jujuba
syrup, PEG polyethylene glycol.
Characteristics ZS group (n = 30) PEG group (n = 32) P-value
WBC (mean ± S.D) 7088.18 ± 0.43 1.48 ± 0.26 0.181
Hemoglobin (mean ± S.D) g/dL 11.82 ± 1.07 12.49 ± 1.05 0.026
Platelet (mean ± S.D) 303.05 ± 70.93 297.40 ± 78.90 0.791
Blood sugar (mean ± S.D) mg/dL 94.81 ± 14.54 87.58 ± 12.78 0.081
Sodium (mean ± S.D) 137.42 ± 1.89 138.77 ± 2.68 0.066
Potassium (mean ± S.D) 4.18 ± 0.23 4.33 ± 0.44 0.146
Calcium (mean ± S.D) 9.86 ± 0.62 9.61 ± 0.50 0.147
Phosphorus (mean ± S.D) 4.74 ± 0.82 4.88 ± 0.83 0.581
AST (mean ± S.D) U/L 31.21 ± 7.08 35.72 ± 19.24 0.258
ALT (mean ± S.D) U/L 15.16 ± 5.23 20.14 ± 16.62 0.211
Bun (mean ± S.D) mg/dL 14.85 ± 4.97 15.51 ± 7.30 0.722
Creatinine (mean ± S.D) mg/dL 0.65 ± 0.14 0.59 ± 0.12 0.159
TSH (mean ± S.D) 2.05 ± 0.67 2.96 ± 1.65 0.023
FT4 (mean ± S.D) 9.80 ± 6.50 8.74 ± 5.91 0.562
Tab le 3. Comparison of baseline laboratory data in the ZS and PEG groups. ZS Ziziphus jujuba syrup,
PEG polyethylene glyco, S.D standard deviation, WBC white blood cell, AST aspartate aminotransferase,
ALT Alanine transaminase, TSH thyroid stimulating hormone, FT4 free thyroxine.
Scientic Reports | (2025) 15:1674 5
| https://doi.org/10.1038/s41598-025-85801-w
www.nature.com/scientificreports/
Content courtesy of Springer Nature, terms of use apply. Rights reserved
catechol, tannin, essential oil, 13 types of amino acids, selenium, calcium, phosphorus, iron, cAMP, and cGMP31.
Its toxicity has been investigated in mice and doses up to 150g/kg did not show any signs of toxicity. LD50 for
intraperitoneal injection was 14g/kg e LD50 for intraperitoneal injection was 14g/kg36.
In a double-blind clinical trial, the ecacy of Ziziphus jujuba extract for chronic idiopathic constipation
in adults was examined, using both subjective self-reports and objective measurement of transit time. eir
ndings demonstrated that Ziziphus jujuba is eective for the treatment of chronic constipation. e transit time
was markedly improved in the treatment group. Furthermore, most patients expressed their satisfaction with the
treatment based on the severity of symptoms and quality of life questionnaire32.
In this study, we found that the most abundant carbohydrate in standardized ZS is fructose, with 40 g/100
g of dried extract. In an in vivo experimental study on hamsters, the dried extract of Ziziphus jujuba (82.4g/
kg of dried jujube) was shown to have high water-soluble carbohydrates (77% by weight on a moisture-free
basis). eir results suggested that feeding diets with medium and high doses of water-soluble carbohydrate
concentrate extract (5–15g/kg of diet) signicantly shortened transit time and improved intestinal motility in
comparison with the control group. e fecal moisture content in the group with medium- and high-dose diets
was considerably higher than the control group. It was concluded that a signicant reduction in transit time
decreases water reabsorption in the intestinal lumen, which leads to an increase in moisture retention in feces.
ese changes may have a substantial impact on the intestinal mucosa by reducing exposure to toxic ammonia
and other harmful contents37.
In a clinical trial study on 121 neonates, the eect of Ziziphus Jujuba extract and phototherapy on the
reduction of bilirubin level and also the hospitalization period for neonatal jaundice were examined. Patients were
compared into two groups. In the intervention group, 1cc/kg of Ziziphus Jujuba extract was given orally three
times a day in addition to phototherapy and was compared with another group that received only phototherapy.
is study revealed that administration of Ziziphus Jujuba extract can lead to bilirubin excretion in neonates
owing to laxative eects and increased urine output. ZS is prepared from the extract of a naturally growing
fruit and contains several compounds. Now, we cannot attribute the laxative eect to a particular ingredient. In
Fig. 2. Comparison of clinical ndings at baseline, 2, 4, 8, and 12 weeks of follow-up in the PEG and ZS
groups using the general linear model. (a) Number of defecation; e upper curve, representing the ZS group,
shows an increase in the frequency of defecation with a much faster course. (b) Fecal encopresis; e lower
curve representing the ZS group shows a decrease in the frequency of fecal encopresis over time, but the
upper curve shows an increasing trend despite a good decrease in the rst 4 weeks. (c) VAS pain score; e
lower curve that represents the ZS group indicates a signicant decrease over time. (d) Fecal consistency; e
dierence between the two groups is not statistically signicant.
Scientic Reports | (2025) 15:1674 6
| https://doi.org/10.1038/s41598-025-85801-w
www.nature.com/scientificreports/
Content courtesy of Springer Nature, terms of use apply. Rights reserved
a previous study, it was contributed to a form of anthraquinone, as contained in senna and other plant-based
laxatives32. However, according to the analysis of ingredients in our study, it could also be attributed to its high
fructose content and high total phenolic content.
is was the rst clinical trial in evaluating the ecacy of standardized ZS in functional constipation. We also
assessed patients’ medication adherence in each follow-up.
Limitation
e primary limitation of this investigation was the lack of an objective index for assessing the improvement
of constipation, which can be considered in future research by measuring colonic transit time. Long-term drug
safety should also be assessed. We educated all parents about proper diet, behavioral modications, and proper
physical activity. As the study did not include any measurement tools to evaluate these aspects among patients,
this should be considered as another potential limitation.
Conclusion
ZS is a potentially safe and eective therapeutic choice for functional constipation without adverse eects and
can be prescribed for at least 3 months. Further investigations are recommended to assess the long-term ecacy
and safety of the syrup using both subjective and objective methods.
Data availability
e data that support the ndings of this study are available from the corresponding author upon reasonable
request.
Received: 3 August 2024; Accepted: 6 January 2025
References
1. Yokoi, A. & Kamata, N. e usefulness of olive oil enema in children with severe chronic constipation. J. Pediatr. Surg. 56 (7),
1141–1144 (2021).
2. Loening-Baucke, V., Krishna, R. & Pashankar, D. S. Polyethylene glycol 3350 without electrolytes for the treatment of functional
constipation in infants and toddlers. J. Pediatr. Gastroenterol. Nutr. 39 (5), 536–539 (2004).
3. Leung, A. K. & Hon, K. L. Paediatrics: How to Manage Functional Constipation. Drugs Context. 10 (2021).
4. Koppen, I. J. et al. Management of functional constipation in children: therapy in practice. Pae diat r. Dr ugs . 17 (5), 349–360 (2015).
5. Dehghani, S. M. et al. Clinical manifestations among children with chronic functional constipation. Middle East. J. Dig. Dis. 7 (1),
31–35 (2015).
6. Lacy, B. E. et al. Bowel disorders. Gastroenterology 150 (6), 1393–1407 e5 (2016).
7. Mugie, S. M., Benninga, M. A. & Di Lorenzo, C. Epidemiology of constipation in children and adults: a systematic review. Best
Pract. Res. Clin. Gastroenterol. 25 (1), 3–18 (2011).
8. Rajindrajith, S. & Devanarayana, N. M. Constipation in children: novel insight into epidemiology, pathophysiology and
management. J. Neurogastroenterol. Motil. 17 (1), 35 (2011).
Fig. 3. Comparison of the medication adherence based on the 4-item Morisky scale at 2, 4, 8, and 12 weeks of
follow-up in the PEG and ZS groups.
Scientic Reports | (2025) 15:1674 7
| https://doi.org/10.1038/s41598-025-85801-w
www.nature.com/scientificreports/
Content courtesy of Springer Nature, terms of use apply. Rights reserved
9. Van Den Berg, M. M., Benninga, M., Di, C. & Lorenzo Epidemiology of childhood constipation: a systematic review. O. J. Am.
Coll. Gastroenterol. ACG. 101 (10), 2401–2409 (2006).
10. Hyams, J. S. et al. Childhood functional gastrointestinal disorders: child/adolescent. Gastroenterology 150 (6), 1456–1468e2 (2016).
11. van Mill, M. J., Koppen, I. J. N. & Benninga, M. A. Controversies in the management of functional constipation in children. Curr.
Gastroenterol. Rep. 21 (6), 23 (2019).
12. Robin, S. G. et al. Prevalence of pediatric functional gastrointestinal disorders utilizing the Rome IV Criteria. J. Pediatr. 195,
134–139 (2018).
13. Chang, S. H. et al. Prevalence, clinical characteristics, and management of functional constipation at pediatric gastroenterology
clinics. J. Korean Med. Sci. 28 (9), 1356–1361 (2013).
14. Hyams, J., Van, T. M. et al. Van TM. Functional disorders: children and adolescents. Gastroenterology 150 (6), 1456–1468 (2016).
15. Benninga, M. A. et al. Childhood functional gastrointestinal disorders: neonate/toddler. Gastroenterology. (2016).
16. Toporovski, M. S. et al. Eect of Polydextrose/Fructooligosaccharide mixture on constipation symptoms in children aged 4 to 8
years. Nutrients. 13(5). (2021).
17. Ansari, H. et al. Factors relating to hospitalisation and economic burden of paediatric constipation in the state of Victoria,
Australia, 2002–2009. J. Paediatr. Child. Health. 50 (12), 993–999 (2014).
18. Rajindrajith, S. et al. Childhood constipation as an emerging public health problem. World J. Gastroenterol. 22 (30), 6864–6875
(2016).
19. Tabbers, M. et al. Evaluation and treatment of functional constipation in infants and children: evidence-based recommendations
from ESPGHAN and NASPGHAN. J. Pediatr. Gastroenterol. Nutr. 58 (2), 258–274 (2014).
20. Rahhal, R. & Uc, A. In Functional Constipation. Pediatric Gastrointestinal Disease-Physiology, Diagnosis, Management. 5th edn.
(eds Walker, R. E., Kleinman, I. R., Sanderson, O.) 675–682 (BC Decker, 2008).
21. Medina-Centeno, R. Medications for constipation in 2020. Curr. Opin. Pediatr. 32 (5), 668–673 (2020).
22. Gomes, P. et al. Polyethylene glycol in the treatment of chronic functional constipation in children. Rev. Paul Pediatr. 29 (2),
245–250 (2011).
23. Gordon, M. et al. Osmotic and stimulant laxatives for the management of childhood constipation. Cochrane Database Syst. Rev.
2016(8).
24. Mearin, F. et al. Clinical practice guideline: irritable bowel syndrome with constipation and functional constipation in the adult.
Rev. Esp. Enferm Dig. 108 (6), 332–363 (2016).
25. Salari, P., Nikfar, S. & Abdollahi, M. A meta-analysis and systematic review on the eect of probiotics in acute diarrhea.
Inammation & allergy-drug targets (formerly current drug targets-inammation & allergy)(discontinued). 11(1), 3–14 (2012).
26. Pahuja, M. et al. Hydroalcoholic extract of Zizyphus jujuba ameliorates seizures, oxidative stress, and cognitive impairment in
experimental models of epilepsy in rats. Epilepsy Behav. 21 (4), 356–363 (2011).
27. Salimi, M. et al. Evaluation of anti-melanogenic activity of Zizyphus jujuba fruits obtained by two dierent extraction methods.
Res. J. Pharmacognosy. 3 (2), 1–7 (2016).
28. Sobhani, Z. et al. erapeutic eects of Zizyphus jujuba Mill. Fruit in traditional and modern medicine: a review. Med. Chem. 16
(8), 1069–1088 (2020).
29. Ebrahimimd, S., Ashkani-Esfahani, S. & Poormahmudibs, A. Investigating the ecacy of Zizyphus jujuba on neonatal jaundice.
Iran. J. Pediatr. 21 (3), 320–324 (2011).
30. Irannejad Niri, Z. et al. e eect of dried Ziziphus Vulgaris on glycemic control, lipid prole, apo-proteins and hs-CRP in patients
with type 2 diabetes mellitus: a randomized controlled clinical trial. J. Food Biochem. 45 (3), e13193 (2021).
31. Flemming, T. et al. PDR for Herbal Medicines (Medical Economics Co., 2000).
32. Naali, T. et al. Zizyphus jujuba extract for the treatment of chronic idiopathic constipation: a controlled clinical trial. Digestion 78
(4), 224–228 (2008).
33. Mozaarpur, S. A. et al. e eect of cassia stula emulsion on pediatric functional constipation in comparison with mineral oil: a
randomized, clinical trial. Daru 20 (1), 83 (2012).
34. Karami, H., Khademloo, M. & Parisa, N. Polyethylene glycol versus paran for the treatment of childhood functional constipation.
Iran. J. Pediatr. 19 (2009).
35. B erry, S. D. et al. Poor adherence to medications may be associated with falls. J. Gerontol. Biol. Sci. Med. Sci. 65 (5), 553–558 (2010).
36. Huang, K. C. e Pharmacology of Chinese Herbs: Second Edition (CRC, 1998).
37. Huang, Y. L. et al. Eects of water-soluble carbohydrate concentrate from Chinese jujube on dierent intestinal and fecal indices.
J. Agric. Food Chem. 56 (5), 1734–1739 (2008).
Author contributions
S.M., F.K., A.S., and S.S. designed the study. F.K. and A.S. participated in syrup preparation. S.M. visited the
patients and F.K. allocated the drugs and collected the data. S.S. performed the statistical analysis. A.P. contrib-
uted to data interpretation. F.K., S.M., and A.S. wrote the rst dra of the manuscript. All authors contributed to
revising the manuscript and approved the nal version of the submitted manuscript.
Declarations
Competing interests
e authors declare no competing interests.
Additional information
Supplementary Information e online version contains supplementary material available at h t t p s : / / d o i . o r g / 1
0 . 1 0 3 8 / s 4 1 5 9 8 - 0 2 5 - 8 5 8 0 1 - w .
Correspondence and requests for materials should be addressed to S.M.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and
institutional aliations.
Scientic Reports | (2025) 15:1674 8
| https://doi.org/10.1038/s41598-025-85801-w
www.nature.com/scientificreports/
Content courtesy of Springer Nature, terms of use apply. Rights reserved
Open Access is article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives
4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in
any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide
a link to the Creative Commons licence, and indicate if you modied the licensed material. You do not have
permission under this licence to share adapted material derived from this article or parts of it. e images or
other third party material in this article are included in the articles Creative Commons licence, unless indicated
otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence
and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to
obtain permission directly from the copyright holder. To view a copy of this licence, visit h t t p : / / c r e a t i v e c o m m o
n s . o r g / l i c e n s e s / b y - n c - n d / 4 . 0 / .
© e Author(s) 2025
Scientic Reports | (2025) 15:1674 9
| https://doi.org/10.1038/s41598-025-85801-w
www.nature.com/scientificreports/
Content courtesy of Springer Nature, terms of use apply. Rights reserved
1.
2.
3.
4.
5.
6.
Terms and Conditions
Springer Nature journal content, brought to you courtesy of Springer Nature Customer Service Center GmbH (“Springer Nature”).
Springer Nature supports a reasonable amount of sharing of research papers by authors, subscribers and authorised users (“Users”), for small-
scale personal, non-commercial use provided that all copyright, trade and service marks and other proprietary notices are maintained. By
accessing, sharing, receiving or otherwise using the Springer Nature journal content you agree to these terms of use (“Terms”). For these
purposes, Springer Nature considers academic use (by researchers and students) to be non-commercial.
These Terms are supplementary and will apply in addition to any applicable website terms and conditions, a relevant site licence or a personal
subscription. These Terms will prevail over any conflict or ambiguity with regards to the relevant terms, a site licence or a personal subscription
(to the extent of the conflict or ambiguity only). For Creative Commons-licensed articles, the terms of the Creative Commons license used will
apply.
We collect and use personal data to provide access to the Springer Nature journal content. We may also use these personal data internally within
ResearchGate and Springer Nature and as agreed share it, in an anonymised way, for purposes of tracking, analysis and reporting. We will not
otherwise disclose your personal data outside the ResearchGate or the Springer Nature group of companies unless we have your permission as
detailed in the Privacy Policy.
While Users may use the Springer Nature journal content for small scale, personal non-commercial use, it is important to note that Users may
not:
use such content for the purpose of providing other users with access on a regular or large scale basis or as a means to circumvent access
control;
use such content where to do so would be considered a criminal or statutory offence in any jurisdiction, or gives rise to civil liability, or is
otherwise unlawful;
falsely or misleadingly imply or suggest endorsement, approval , sponsorship, or association unless explicitly agreed to by Springer Nature in
writing;
use bots or other automated methods to access the content or redirect messages
override any security feature or exclusionary protocol; or
share the content in order to create substitute for Springer Nature products or services or a systematic database of Springer Nature journal
content.
In line with the restriction against commercial use, Springer Nature does not permit the creation of a product or service that creates revenue,
royalties, rent or income from our content or its inclusion as part of a paid for service or for other commercial gain. Springer Nature journal
content cannot be used for inter-library loans and librarians may not upload Springer Nature journal content on a large scale into their, or any
other, institutional repository.
These terms of use are reviewed regularly and may be amended at any time. Springer Nature is not obligated to publish any information or
content on this website and may remove it or features or functionality at our sole discretion, at any time with or without notice. Springer Nature
may revoke this licence to you at any time and remove access to any copies of the Springer Nature journal content which have been saved.
To the fullest extent permitted by law, Springer Nature makes no warranties, representations or guarantees to Users, either express or implied
with respect to the Springer nature journal content and all parties disclaim and waive any implied warranties or warranties imposed by law,
including merchantability or fitness for any particular purpose.
Please note that these rights do not automatically extend to content, data or other material published by Springer Nature that may be licensed
from third parties.
If you would like to use or distribute our Springer Nature journal content to a wider audience or on a regular basis or in any other manner not
expressly permitted by these Terms, please contact Springer Nature at
onlineservice@springernature.com
ResearchGate has not been able to resolve any citations for this publication.
Article
Full-text available
Constipation is a frequent problem in children. We evaluated the effect of a mixture (polydextrose [PDX] and fructooligosaccharide [FOS]) in children with constipation. We performed a prospective interventional study with a mixture (PDX 4.17 g and FOS 0.45 g) in a daily dose of food supplement. The intervention lasted 45 days, with visits at 15, 30, and 45 days after administration. The sample comprised 105 patients, of whom 77 completed the intervention. A statistically significant reduction in the frequency of symptoms was observed at the end of the study. The frequency of children with fewer than three bowel movements per week dropped from 59.7% to 11.7%, and there was a decrease in the frequency of Bristol type 1 and 2 dry stools (68.8% to 7.8%), pain on defecation (79.2% to 10.4%), and fear of defecation (68.8% to 3.9%). The proportion of children with abdominal pain symptoms decreased from 84.2% to 2.6% at the end of the study. A relevant limitation of the present study was the lack of a control group treated with placebo. The administration of the PDX/FOS mixture was accompanied by a significant reduction in the frequency of constipation symptoms of the children evaluated. The tolerability was very good, and the rate of adverse effects was low.
Article
Full-text available
Background: Despite being a common problem in childhood, functional constipation is often difficult to manage. This article provides a narrative updated review on the evaluation, diagnosis and management of childhood functional constipation. Methods: A PubMed search was performed with Clinical Queries using the key term ‘functional constipation’. The search strategy included clinical trials, meta-analyses, randomized controlled trials, observational studies and reviews. The search was restricted to the English literature and to the paediatric population. The information retrieved from the above search was used in the compilation of the present article. Results: A detailed history and thorough physical examination are important in the evaluation of a child with constipation to establish the diagnosis of functional constipation as per the Rome IV criteria and to catch ‘red flags’ suggestive of organic causes of constipation. These ‘red flags’ include delayed passage of meconium, ribbon stool, rectal bleeding/blood in the stool unless attributable to an anal fissure, failure to thrive, severe abdominal distension, absent anal wink/cremasteric reflex, tight and empty rectum on digital examination and explosive expulsion of liquid stool and gas on withdrawal of the finger, hair tuft/dimple/lipoma/haemangioma in the lumbosacral area, and an anteriorly displaced anus. For functional constipation, pharmacological therapy consists of faecal disimpaction and maintenance therapy. This can be effectively accomplished with oral medications, rectal medications or a combination of both. The most commonly used and most effective laxative is polyethylene glycol. Non-pharmacological management consists of education, behavioural modification and dietary interventions. The combination of pharmacological therapy and nonpharmacological management increases the chance of success. Conclusion: Polyethylene glycol is the medication of first choice for both disimpaction and maintenance therapy. If polyethylene glycol is not available or is poorly tolerated, lactulose is the preferred alternative. Other laxatives may be considered as second-line therapy if treatment with osmotic laxatives fails or is insufficient. Maintenance treatment should be continued for at least 2 months. Early treatment will result in a faster and shorter treatment course.
Article
Full-text available
We aimed to evaluate the effect of dried Ziziphus vulgaris [Z. vulgaris] consumption on liver enzymes, blood pressure, inflammatory status, glycemic control, and lipid concentrations in type 2 diabetes patients. Seventy‐six diabetic participants (aged 20–65 years) randomly assigned to intervention (n = 38) and placebo (n = 38) groups. The intervention group received 30 g/day dried Z. vulgaris for 12 weeks. At the end of the study, there was a significant reduction in the percentage change of weight, body mass index [BMI], insulin, homeostasis model assessment‐insulin resistance [HOMA‐IR], Apoprotein B100 [ApoB100], and high‐sensitive c‐reactive protein [hs‐CRP] in the intervention group compared to the controls. Also, increased values of quantitative insulin check index [QUICKI] and Apoprotein A‐I [ApoA‐I] in Z. vulgaris group compared to the controls were observed. In conclusion, consumption of dried Z. vulgaris fruit could have beneficial effects on improving the glycemic control and reducing the cardiovascular risk factors in the diabetic patients. Practical applications In the present study we found that consumption of 30 g/day dried Z. vulgaris fruit in patients with type 2 diabetes for 12 weeks has beneficial anti‐inflammatory, anti‐hyperglycemic, and anti‐hyperlipidemic effects on type 2 diabetes mellitus [T2DM] patients compared to the control group. Thus, it seems reasonable to design a large‐scale clinical trial to determine the potential adverse effects of higher doses of this fruit and identify the therapeutic doses for the complementary treatment in T2DM medication. The medication with this popular fruit as an ingredient could be easily accepted by diabetic patients and may reduce the dependency and dosage of some of the routine diabetes medications which often have some adverse side effects.
Article
Full-text available
Ziziphus jujuba Mill. belonging to the Rhamnaceae family, has been consumed since ancient times as a medicine and food. In the different traditional medical schools, Z. jujuba has been used to treat various diseases such as respiratory system diseases (asthma, cough, and laryngitis), gastrointestinal problems (constipation, colitis and liver diseases), as well as, cardiovascular and genitourinary system diseases. From the perspective of Islamic traditional medicine (ITM) Z.jujuba fruit is an emollient, laxative, and maturative, it can purify blood and improve blood circulation, relieve internal heat and reduce inflammation. Some therapeutic uses of Z. jujuba such as antibacterial, antioxidant, sedative, hepato-protective, anti-hyperglycemic, and anti-hyperlipidemic activities have been shown in modern pharmacological studies. In the current study, traditional and ethno-medicinal uses, botany, phytochemistry and pharmacological activities of Z. jujuba were reviewed.
Article
Full-text available
Purpose of review Functional constipation (FC) in children is a common health problem with reported worldwide prevalence rates up to 32.2%. The majority of children with constipation respond to oral laxative treatment. After 5 years of intensive treatment, however, approximately 50% of children remain symptomatic. To discuss the evidence for new treatments in these children, including pre- and probiotics, pelvic physiotherapy, prucalopride, sacral nerve stimulation, and surgery, and to highlight the controversies surrounding them. Recent findings Pre- and probiotics and prucalopride are not effective in the treatment of childhood constipation. Pelvic physiotherapy and sacral nerve stimulation are promising treatment options but larger trials are needed. Surgery for pediatric constipation is the treatment of last resort. Summary Large, well-designed placebo-controlled trials with proper outcome measures, as suggested by the Rome foundation pediatric subcommittee on clinical trials, are necessary to provide more insight regarding the efficacy of new treatments in childhood constipation.
Article
Objectives We have recently reported the safety and efficacy of polyethylene glycol 3350 without electrolytes (PEG) for the daily treatment of constipation in older children. Because there are very few data available on the use of PEG in infants and toddlers, we evaluated the efficacy and safety of PEG for the treatment of constipation in children <2 years of age. Methods This is a retrospective chart review of 75 constipated children <2 years of age at start of PEG therapy. PEG was started at an average dose of 1 g/kg body weight/d and parents were asked to adjust the dose to yield 1 to 2 soft painless stools/d. Data from the history and physical examination were collected initially and at short‐term (≤4 months) and long‐term (≥6 months) follow‐up. Results 75 otherwise healthy children received PEG for functional constipation. The mean age was 17 months (range, 1 to 24 months) and the mean duration of constipation was 10 months (range, 0.5 to 23 months). The mean duration of short‐term follow‐up was 2 months and mean duration of long‐term follow‐up was 11 months. The mean effective short‐term PEG dose was 1.1 g/kg body weight/d and the mean long‐term dose was 0.8 g/kg body weight/d. Constipation was relieved in 85% with short‐term and in 91% with long‐term PEG therapy. Adverse effects were mild and included diarrhea, which disappeared with lowering the dose. No subjects stopped PEG because of adverse effects. Conclusion PEG is effective, well tolerated and appeared safe for the treatment of functional constipation in children <2 years of age.
Article
Purpose : Few reports have determined the efficacy of olive oil enemas for severe constipation. Here, we review our experience with olive oil enemas in children with severe chronic constipation. Methods : In our outpatient Pediatric Surgery Department, the charts of 118 patients prescribed with olive oil enemas between January 2010 and November 2019 were retrospectively reviewed. A 1–2 ml/kg olive oil enema was given either alone or followed several hours later by a glycerin enema. Ratings included “very effective (VE),” “effective (E),” “limited (L),” “ineffective (I),” and “unknown (U).” Results : One hundred and fifteen (97.5%) patients were able to use olive oil enemas at home. Forty-nine had functional constipation; 43 had anorectal malformation; 40 had Hirschsprung disease; 12 had spina bifida; and 10 had other maladies. Used as an enema, olive oil was effective in treating fecal impaction in 77.6% of patients; as a lubricant, it was effective in treating 76.9% of patients. Efficacy for fecal disimpaction was similar among patients with different underlying disorders. Conclusion : Olive oil enemas are useful for more than three-quarters of children with severe chronic constipation. Further study is warranted to add olive oil enemas as an adjunctive treatment in the management of severe constipation.
Article
Purpose of review: Chronic constipation is a common problem that substantially impacts the quality of life of patients and families, healthcare professionals, and resources. The purpose of this review is to discuss the medications that are available for management of chronic constipation, including medications that have been approved by the FDA for adults, other been studied in pediatrics now, and might become available within the upcoming years. Recent findings: Recent developments in the evaluation of childhood constipation are providing a better understanding into defecation disorders in children and not only new therapies are becoming available, including medications, but also other therapies, such as biofeedback for treatment of functional defecation disorders, electrical stimulation, and surgeries. The aim of this article is to provide an update on the medications that are available for management of chronic constipation, especially with the development and study of newer medications, such as Linaclotide and Lubiprostone with promising results in both adult and pediatric patients. Summary: This review will help us identify and have a better understanding regarding what medications are available for use and the indications, so that we can better manage patients with chronic constipation. VIDEO ABSTRACT.
Article
Objective: To assess the prevalence of functional gastrointestinal (GI) disorders in children 0-18 years old according to the newly established Rome IV diagnostic criteria as reported by parents in a representative community sample. Study design: A cross-sectional study in which mothers (n = 1255) of children aged 0-18 years old in the US were recruited to complete an online survey about their child's GI symptoms, quality of life (QoL), and other health conditions. Results: Based on the Rome IV criteria, 24.7% of infants and toddlers aged 0-3 years and 25.0% of children and adolescents aged 4-18 years fulfilled symptom-based criteria for a functional GI disorder. The most common functional GI disorders were infant regurgitation among infants (24.1%) and functional constipation among both toddlers (18.5%) and children and adolescents (14.1%). QoL was diminished in pediatric patients with functional GI disorders (median = 71.69 vs median = 87.60; z = -11.41; P < .001). Children were more likely to qualify for a functional GI disorder if their parent qualified for a functional GI disorder (35.4% vs 23.0%; P < .001). Conclusions: Based on Rome IV criteria, functional GI disorders are common in pediatric populations of all ages and are associated with decreased QoL.